NCT04484077View on ClinicalTrials.gov

hCT-MSC Infusion in Adults With Autism Spectrum Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
Autism Spectrum DisorderAutism
Interventions
BIOLOGICAL

hCT-MSC

2x10\^6 hCT-MSC/kg suspended in plasmalyte-A, 5% HSA, and residual DMSO/dextran administered intravenously over 30-60 minutes via syringe pump

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

The Marcus Foundation

OTHER

lead

Joanne Kurtzberg, MD

OTHER